Aadi Bioscience Stock Buy or Sell? AADI Stocks Forecast

Market Capitalization: 46 599 200 $
EBITDA: -69 520 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.404
Trailing PE: -
Forward PE: -
Shares Outstanding: 24525900






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Aadi Bioscience Stock Buy or Sell? AADI Stocks Analytic Forecasts

Updated on February 24, 2024 (09:16)

Aadi Bioscience, Inc. (AADI prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the AADI stock market. Experts share their opinions on what to expect from the Aadi Bioscience, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Aadi Bioscience stocks.

Aadi Bioscience, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy AADI Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Galzus Research and is titled

“Aadi Bioscience: New Data Drives A Beaten Company Down, Not Really Justified”

is published on December 17 (2023) and has 1 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Aadi Bioscience is a biotech company focused on a nanoliposomal encapsulation of the mTOR inhibitor sirolimus.
  • Their drug, nab-sirolimus, has been approved for the treatment of PEComa, a rare soft tissue sarcoma.
  • New findings from their tissue-agnostic trial have been underwhelming, leading to a massive drop in valuation.
  • This drop is not quite fully justified, but AADI remains a risky equity with an unproven pipeline in TSC1/2-altered cancers.

The author starts his analytic review with the following:

Topline Summary Aadi Bioscience (NASDAQ:AADI) is a microcap developmental biotech placing its bets on a single agent, a nanoliposomal encapsulation of the mTOR inhibitor sirolimus. They have one approved indication, with several others being explored in clinical trials. Their tissue-agnostic trial could end up being a massive win for the company, but in the past week we have seen a key data update that has not been received well by the market. However, I’m going to lay out why it’s going to take until early 2025 to know with more clarity. I think this is a company with promise, despite what the market is saying, but I still also believe it’s a bit soon to buy in. This is a hold for me, at least for now. Let’s have a look at their results.

The author declares an interesting position, and the number of his followers is 520 and it grows, but not that weighty compared to other authors.
Galzus Research has 70 works published.
The contributor of experts community since 2021


One more noteworthy article is written by Busted IPO Forum under the title

“Aadi Bioscience: High Risk/High Reward”

on June 29 (2023) and has 0 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add AADI stocks to your investment portfolio or not, and helps to work out your own Aadi Bioscience stock selling strategies:

  • Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc.
  • The firm’s main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types.
  • An investment analysis follows in the paragraphs below.

Busted IPO Forum starts analysis with such words:

You cannot swim for new horizons until you have courage to lose sight of the shore.”― William Faulkner

The opinion of the author can be considered quite authoritative.
The number of 8177 followers confirms this.
Busted IPO Forum is the contributor of experts community since 2017. Has already published at least 561 articles.


Another analysis presented by Avisol Capital Partners came out on March 6 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for AADI stocks. It sounds like

“Aadi Bioscience: Commercial Stage With Large Market In Label Expansion”

Article has got 1 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the Aadi Bioscience, Inc., the expert says the following:

  • AADI is a commercial stage company with a potential label expansion ahead.
  • It is adequately funded, run by expert management, and has a major catalyst next year.
  • All told, AADI looks good.

And here, what comes first:

Aadi Bioscience (NASDAQ:AADI) is a commercial stage oncology drug developer working with the mTOR pathway. Lead asset FYARRO (nab-sirolimus) is an albumin-bound sirolimus approved for advanced malignant PEComa (perivascular epithelioid cell tumors), a type of rare cancer occurring in the soft tissues of internal organs. The company’s exclusive focus is on cancers that are highly mTOR dependent, and it uses a nanoparticle albumin-based (nab) platform validated by paclitaxel. Fyarro is licensed from Celgene, and in the initial years, Celgene also funded the company. The company was founded and is led by Neil Desai, PhD, a co-creator of abraxane, along with Patrick Soon-Shiong, at Abraxis.

This author is very popular among the auditory. He has 16485 followers.

Avisol Capital Partners is the contributor of experts community since 2017 and has at least 1923 analytic reviews published.


The Share Price of Aadi Bioscience, Inc. (AADI) for now

What analysts predict: $11.67
52-week high/low: $11.82 / $1.55

50/200 Day Moving Average: $2.295 / $5.04

The average stock price over the previous 50/200 days. For Aadi Bioscience stocks, the 50-day moving average is the resistance level for now. For AADI stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for AADI stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.